CRS 2017: Advancing Hyperlipidemia Treatment: Integrating PCSK9 Inhibitors into Optimal Treatment Plans

October 21, 2017 at 9:30am

Michael J Bloch will discuss the appropriate incorporation of PCSK9 inhibitors for the lowering of LDL-C in patients with hypercholesterolemia in his upcoming presentation, “Advancing Hyperlipidemia Treatment: Integrating PCSK9 Inhibitors into Optimal Treatment Plans.”

He will begin with a discussion of statin therapy, including an overview of available statins, potential side effects, and the potential for statin intolerance, as well as the assessment of risk for cardiovascular events in patients with hypercholesterolemia.

Next, he will answer the question “Which non-statin medications are there to choose from that are supported by data?,” discussing ezetimibe, niacin, fibrates, and bile acid sequestrants, and where PCSK9 inhibitors fit into these considerations.

Lastly, he will review the practical considerations for prescribing PCSK9 inhibitors, including cost, formulary issues, and utilization criteria.

—Michael Potts

Reference:

Bloch MJ. Advancing hyperlipidemia treatment: integrating PCSK9 inhibitors into optimal treatment plans [presented at Cardiometabolic Risk Summit 2017]. Dallas, Texas. October 21, 2017.